- Home
- XIN vs NRSN Comparison
XIN vs NRSN Comparison
Compare XIN & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XIN
- NRSN
- Stock Information
- Founded
- XIN 1997
- NRSN 2017
- Country
- XIN China
- NRSN Israel
- Employees
- XIN N/A
- NRSN N/A
- Industry
- XIN Homebuilding
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- XIN Consumer Discretionary
- NRSN Health Care
- Exchange
- XIN Nasdaq
- NRSN Nasdaq
- Market Cap
- XIN 15.9M
- NRSN 17.8M
- IPO Year
- XIN N/A
- NRSN 2021
- Fundamental
- Price
- XIN $2.82
- NRSN $1.09
- Analyst Decision
- XIN
- NRSN Hold
- Analyst Count
- XIN 0
- NRSN 1
- Target Price
- XIN N/A
- NRSN N/A
- AVG Volume (30 Days)
- XIN 21.5K
- NRSN 374.5K
- Earning Date
- XIN 01-01-0001
- NRSN 12-18-2024
- Dividend Yield
- XIN N/A
- NRSN N/A
- EPS Growth
- XIN N/A
- NRSN N/A
- EPS
- XIN N/A
- NRSN N/A
- Revenue
- XIN $667,143,185.00
- NRSN N/A
- Revenue This Year
- XIN N/A
- NRSN N/A
- Revenue Next Year
- XIN N/A
- NRSN N/A
- P/E Ratio
- XIN $0.32
- NRSN N/A
- Revenue Growth
- XIN N/A
- NRSN N/A
- 52 Week Low
- XIN $2.24
- NRSN $0.51
- 52 Week High
- XIN $7.05
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- XIN 50.53
- NRSN 47.35
- Support Level
- XIN $2.53
- NRSN $1.01
- Resistance Level
- XIN $2.86
- NRSN $1.13
- Average True Range (ATR)
- XIN 0.24
- NRSN 0.09
- MACD
- XIN 0.04
- NRSN -0.01
- Stochastic Oscillator
- XIN 69.35
- NRSN 27.27
About XIN Xinyuan Real Estate Co Ltd
Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.